Immusoft CEO Matthew Scholz.

Immusoft raises cash from Tim Draper, others to program human cells that fight diseases

Applying computer science principles to human anatomy may end up producing a medical breakthrough if one Seattle startup has its way. Immusoft has raised another $2.3 million of a $3 million round that it will use to continue developing a unique method of manipulating human immune cells. Investors backing the company include venture capitalist Tim Draper (personally… Read More


GeekWire Radio: Amgen and the state of Seattle biotech, with guest Luke Timmerman

Amgen dealt a blow to Seattle’s biotech industry last week with the announcement that it will be closing its large research-and-development campus on Elliott Bay, which dates back to its acquisition of Immunex more than a decade ago. So what does this closure mean for the biotech industry? Our guest this week is Luke Timmerman, the veteran biotechnology journalist, who… Read More


Cancer research company Immune Design raises $60M in IPO

Trading on the NASDAQ under the ticker IMDZ, Seattle biotech company Immune Design today priced its initial public offering at $12 per share and raised $60 million. The company, which is working on novel technologies that activate the body’s immune system to fight cancer, had previously set its IPO range at $12 to $14 per share with… Read More


Seattle biotech firm Kineta raises $1.6 million to boost its battle against disease

Kineta, a Seattle-based biotech startup, has raised an investment round worth almost $1.6 million from existing investors in the company. The investment will be used to fund continued development of the drugs that the company is working on. “This new raise comes from existing investors and shows confidence in what the Kineta team is doing and… Read More


Stratos Genomics lands investment, secures partnership with biotech giant Roche

Seattle biotech company Stratos Genomics today announced a new partnership with Roche, a Switzerland-based biotech giant. Roche has made a strategic investment in Stratos to support development of the company’s technology, called Sequencing By Expansion (SBX), which converts DNA into more easily-read polymer and makes it cheaper and faster to sequence DNA. Roche, a leader in research-focused healthcare that employs more… Read More


Stratos Genomics raises $10M for DNA sequencing technology

Stratos Genomics, a Seattle-based biotech company, has raised $10 million of a $16.3 million series B round. CEO Allan Stephan confirmed the new funding with us today, but wouldn’t disclose investors. Founded in 2007, Stratos Genomics is a spin-off of Seattle-based Stratos Group. The company builds technology called Sequencing By Expansion, or “SBX,” which converts DNA into more easily-read polymer, making… Read More


Cardiac Dimensions raises $20M to sell heart-valve repair technology

AlCardiac Dimensions, a Kirkland-based company building heart-valve repair technology, today announced a $20 million round of financing led by M. H. Carnegie & Co. and Lumira Capital. Founded in 2001, Cardiac Dimensions has developed a way to address cardiovascular conditions with its Carillon Mitral Contour System, a non-surgical device that treats a form of congestive heart failure… Read More

Oricula Therapeutics CEO Malcolm Gleser.

UW spin-out Oricula Therapeutics raises cash to sell medicine that prevents hearing loss

Oricula Therapeutics, a startup spun out of the University of Washington, has raised $122,000 to commercialize medicine that can help prevent hearing loss. Founded in 2013, Seattle-based Oricula grew out of research done at the UW that uncovered ways to help patients maintain good hearing after taking antibiotics for serious infections. The startup has licensed… Read More


More funding for cancer research in Seattle: Adaptive Biotechnologies raises $105M

Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same day the Fred Hutchinson Cancer Research Center announced a $20 million donation from the family of CEO Jeff Bezos, Seattle-based Adaptive Biotechnologies announced a big $105 million investment. Adaptive, which had previously only raised $15 million, was… Read More

Video thumbnail for youtube video Seattle biotech company Acucela preps for $125M IPO on Tokyo Exchange

Seattle biotech company Acucela preps for $125M IPO on Tokyo Exchange

Seattle biotechnology company Acucela is prepping for a $125 million IPO on the Tokyo Exchange. An SEC filing published today reveals that Acucela, which is developing technologies to treat blinding eye diseases, posted a profit of $5.1 million in 2013 through Sept. 30. Since 2008, the clinical-stage company made its money via a partnership with Otsuka,… Read More


Tech Moves: Prevencio lands biotech vets; Lively hires music vets; DomainTools nabs Roberts

—Prevencio, an early-stage biotech company working on cardiac biomarker tests, has named H. Perry Fell as chairman and Rhonda Rhyne as president and CEO. Fell is a well-known Seattle area biotech leader, having previously served as CEO of NanoString Technologies and Seattle Genetics. Rhyne is the former president of CardioDynamics, which sold to SonoSite in… Read More

Bruce Montgomery

Bruce Montgomery biotech startup Cardeas Pharma raises $34 million

It has been a good week for the Seattle life sciences community. On Monday, Seattle genomics tool maker NanoString Technologies filed for an initial public offering that could raise up to $86 million. Now, comes word that Cardeas Pharma Corporation, a biopharmaceutical company led by Seattle biotech veteran Bruce Montgomery, has raised $34 million in funding…. Read More


Former oil trader, Yankees part-owner invests in Kineta

Seattle-based biotech upstart Kineta announced a new investment partnership with RLB Holdings, a Connecticut-based investment firm that partially owns the New York Yankees and is managed by a former Glencore international oil trader. Actual numbers weren’t released, but RLB invested in two of Kineta’s clinical stage drug programs: Kineta One LLC and Kineta Two LLC. Between Kineta… Read More


Report: Cardeas Pharma raises $5M

Cardeas Pharma, a biotechnology company led by Seattle biotech entrepreneur Bruce Montgomery, has reeled in $5 million in venture financing from Novo Ventures, Avalon Ventures, WRF Capital and others, reports Xconomy. The round is expected to close with up to $7.5 million. Montgomery is a well regarded biotech leader, having previously sold Corus Pharma to Gilead Sciences… Read More


Biotech veteran Henney inducted into Hall of Fame

Biotech pioneer Christopher Henney has been inducted into the industry’s Hall of Fame, with the announcement made at the annual Biotech CEO Meeting in Laguna Beach, California. Henney is credited with co-founding Immunex, Dendreon and Icos, three of the most important biotechnology companies to emerge in the Seattle area in the past 30 years He… Read More


Dendreon cuts 500 jobs, sheds a quarter of its workforce

Slower-than-expected uptake of its Provenge prostate cancer drug forced Seattle biotech company Dendreon to announce 500 job cuts this afternoon, following through on a restructuring plan announced a month ago. The company had employed more than 1,900 people as of the end of June, about 1,200 of them in its manufacturing operations. Dendron also said… Read More


Tech Moves: Datacastle hires Craig Blessing; Opscode co-founder Jesse Robbins honored; and more

Datacastle, a Seattle company that helps organizations securely protect data as employees access corporate resources via the Web and mobile devices, has named Craig Blessing as vice president of sales and business development. Blessing previously worked at Apple Computer, N2H2, Opsware and most recently Doyenz. “The dramatic growth of laptops and edge devices for enterprise… Read More